Carrick Therapeutics - Establishment of US operations and new CEO
CARRICK THERAPEUTICS ANNOUNCES PLAN TO ESTABLISH US OPERATIONS AND APPOINTMENT OF TIM PEARSON AS CEO
Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has today announced that it plans to establish business operations in
"The board of directors has made the decision to expand company operations in
"As a founder of Carrick and CEO since 2016, I am very proud of the accomplishments of our team and the creation of a multi-asset portfolio of clinical-stage drugs targeting critical pathways that drive aggressive and resistant cancers," said Elaine Sullivan. "It is now time for a new phase of growth fuelled by new funding and talent. I am excited about my new role and look forward to supporting the future success of the company and the board of directors as Carrick expands."
Company board member Paul Thurk, of ARCH Venture Partners, said: "With this transition, we are excited to add the leadership of Tim Pearson as CEO with 20 years of experience building successful biotechnology companies and oncology drug development, previously leading significant functions with TESARO and MedImmune."
Tim Pearson commented: "Now is an exciting time to be joining Carrick as the pipeline develops and provides more robust evidence of the benefits to targeting CDK7 and Folate Receptor Alpha. I am honored to join such a talented management team and exceptional collaborators in the mission of transforming cancer treatments and the lives of cancer patients. I look forward to working with the board and leading Carrick in the years ahead."
Mr. Pearson brings a track record of growing biotech companies from R&D stage through commercialization, along with significant fund raising and strategic business development. He most recently held the position of Executive Vice President and Chief Financial Officer for TESARO, a public oncology-focused biopharmaceutical company acquired by GSK in January of 2019. Prior to that, he was Chief Financial Officer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over
Carrick is privately held with headquarters in
Charlotte Street Partners, tel: +44 7880 204256
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
Released June 28, 2019